February 8, 2017

US Veterans Enroll in First Trial of Marijuana for Chronic PTSD

February 8, 2017
US Veterans enroll - ptsd marijuana cannabis

I received a press release from one of my favorite organizations, Multidisciplinary Association for Psychedelic Studies (MAPS). I was excited to learn that US Veterans have a chance to enroll in the first trial of marijuana for chronic PTSD (post traumatic stress syndrome).

In my time as an activist I have heard from hundreds of US Veterans expressing their desire to have safe access to medical marijuana to help treat an array of health issues. It seems to me that the number one issue US Veterans want access to medical marijuana is to treat PTSD, and I wholeheartedly support that. Depriving Veterans from access to marijuana and forcing them to use harmful prescription drugs is an atrocity, I am glad to hear that this trial is taking place.

You can read the full press release here:

Half of the subjects will be enrolled at SRI in Phoenix, Ariz., led by Co-Investigator/Site PI Sue Sisley, M.D., and the other half at Johns Hopkins University in Baltimore, Maryl., led by Co-Investigator/Site PI Ryan Vandrey, Ph.D. Participant screening commenced on January 2, 2017, at SRI, and the first participant was officially enrolled on February 3. Johns Hopkins University commenced screening on January 19.

Both study locations in Phoenix and Baltimore are currently recruiting adult military veterans who experienced trauma during military service. Study volunteers will complete 17 outpatient study visits to the respective clinics over 12 weeks and a six-month follow-up visit. Study visits occur at Scottsdale Research Institute and Johns Hopkins University. For more information on the clinical trial, email [email protected] (SRI-Phoenix) or call 410-550-0050 (JHU-Baltimore).

This study is funded by a $2.156 million grant from the Colorado Department of Public Health and Environment (CDPHE) to the California-based non-profit Multidisciplinary Association for Psychedelic Studies (MAPS), which is sponsoring the research. Since its founding in 1986, MAPS has raised over $36 million for psychedelic therapy and medical marijuana research and education. MAPS is working to evaluate the safety and efficacy of botanical marijuana as a prescription medicine for specific medical uses approved by the FDA.

More information at maps.org


Recent & Related Posts
Recent & Related Posts